Trial Profile
Special drug use survey of Stelara for Crohn's disease
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Mar 2020
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms STL2L
- Sponsors Janssen Pharmaceutical KK
- 12 Oct 2017 Status changed from not yet recruiting to recruiting.
- 03 Jun 2017 New trial record